One size does not fit all—evolution of opioid agonist treatments in a naturalistic setting over 23 years
Addiction2018Vol. 114(1), pp. 103–111
Citations Over TimeTop 10% of 2018 papers
Carlos Nordt, Marc Vogel, Michelle Dey, Andreas Moldovanyi, Thilo Beck, Toni Berthel, Marc Walter, Erich Seifritz, Kenneth M. Dürsteler, Marcus Herdener
Abstract
Based on data from Zurich, Switzerland from 1992 to 2015, there is no evidence for an excessive demand for a single medication in a naturalistic and liberal opioid agonist treatment setting. Rather, the specific patient characteristics associated with each medication underline the need for diversified treatment options for opioid dependence.
Related Papers
- → Attitudes Toward Buprenorphine and Methadone Among Opioid‐Dependent Individuals(2008)127 cited
- → Effects of buprenorphine and methadone in methadone-maintained subjects(1995)123 cited
- → Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study(2020)16 cited
- → Fatal Poisoning in Methadone and Buprenorphine Treated Patients - Are there Differences?(2006)26 cited
- → Treatment of Chronic Methadone Dependence with Buprenorphine(2016)2 cited